Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Factor Xa Inhibitor [EPC]

Known as: Factor 10a Inhibitor, Activated Factor X Inhibitor, Activated Factor 10 Inhibitor 
 
National Institutes of Health

Related topics

Related topics

2 relations

Narrower (1)

Antithrombin III
Factor Xa inhibitors

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Assessment of the effect of direct oral anticoagulants dabigatran, rivaroxaban, and apixaban in healthy male volunteers using a thrombin generation assay
Abstract Essentials The value of thrombin generation assay (TGA) in monitoring direct oral anticoagulants (DOAC) is not well… Expand
Is this relevant?
2016
2016
Resolution of a warfarin and dabigatran-resistant left atrial appendage thrombus with apixaban
The majority of embolisms associated with atrial fibrillation (AF) are from the left atrial appendage (LAA). To treat the… Expand
Is this relevant?
2015
2015
Nontraumatic spinal subdural hematoma complicating direct factor Xa inhibitor treatment (rivaroxaban): a challenging management
PurposeWe report on a 72-year-old male patient who developed a nontraumatic spinal subdural hematoma (SSDH) during rivaroxaban… Expand
  • figure 2
  • figure 1
Is this relevant?
2015
2015
Rivaroxaban Versus Enoxaparin for Venous Thromboembolism Prophylaxis after Hip and Knee Arthroplasty.
The oral Factor Xa inhibitor rivaroxaban (Xarelto) has been the pharmacologic agent used for venous thromboembolism (VTE… Expand
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial…
OBJECTIVES The aim of this study was to determine the risk of major clinical and thromboembolic events after cardioversion for… Expand
  • table 1
  • table 2
Is this relevant?
2014
2014
Safety and efficacy of edoxaban, an oral factor xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan.
Edoxaban, an oral direct factor Xa inhibitor, has proven antithrombotic efficacy. In a multicenter, phase II study, 264 total hip… Expand
  • table 1
  • table 2
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51.
OBJECTIVES The aim of this study was to determine if rivaroxaban is associated with a reduction in stent thrombosis among… Expand
  • table 1
  • figure 1
  • figure 3
  • figure 2
  • figure 4
Is this relevant?
2013
2013
Fondaparinux as an alternative to vitamin K antagonists in haemodialysis patients.
BACKGROUND Accelerated vascular calcification and increased risk of calciphylaxis can be a reason to restrict the use of vitamin… Expand
  • table 1
  • table 2
Is this relevant?
2013
2013
Efficacy and Safety of Apixaban in Patients Following Cardioversion for Atrial Fibrillation: Insights from the ARISTOTLE trial
Objectives: To determine the risk of major clinical and thromboembolic events after cardioversion for atrial fibrillation in… Expand
  • table 1
  • table 2
Is this relevant?
2013
2013
Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects
Background. Darexaban (YM150) is a potent direct factor Xa (FXa) inhibitor developed for the prophylaxis of venous and arterial… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE